LOGIN  |  REGISTER
Cue Biopharma
Astria Therapeutics

Rigel Pharmaceuticals to Participate in Upcoming September Investor Conferences

August 30, 2023 | Last Trade: US$38.85 0.46 -1.17

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:

  • 2023 Wells Fargo Healthcare Conference, September 6-8, 2023, Boston, MA
    Raul Rodriguez will present a company overview on Wednesday, September 6th at 12:45 p.m. ET.

  • Citi's 18th Annual BioPharma Conference, September 6-7, 2023, Boston, MA
    Rigel management will participate in one-on-one meetings on Thursday, September 7th.

To access the live webcast of the Wells Fargo Healthcare Conference presentation, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Investors & Media Contacts:  
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page